People with Type 2 diabetes lost up to 60 pounds on Lilly’s latest weight loss drug
Eli Lilly's experimental drug retatrutide has demonstrated significant weight loss in adults with type 2 diabetes, with participants losing up to 60 pounds. In the TRIUMPH-1 study, patients achieved 28.3% weight loss at 80 weeks. The drug is not yet FDA-approved, but Eli Lilly plans to file for regulatory approval in the first quarter of 2027.
Listen to Live Briefing
Real-time synthesized voice briefing · Live Feeds Desk
- ✓ Participants in the TRIUMPH-1 study achieved 28.3% weight loss at 80 weeks.
- ✓ Patients on the highest dose of retatrutide lost an average of 18.8% of their body weight, compared to 5.1% for those receiving a placebo.
- ✓ Eli Lilly intends to file for regulatory approval of retatrutide in the first quarter of 2027.
- ✓ In TRIUMPH-2, adults with obesity or overweight and type 2 diabetes lost up to an average of 49.6 lbs (20.8%).
What changed
New data from Eli Lilly's TRIUMPH-1 study and other phase 3 trials shows retatrutide's efficacy in weight loss for type 2 diabetes patients, with some participants losing up to 60 pounds.
Live updates
-
Eli Lilly's retatrutide shows 60-pound weight loss in type 2 diabetes patients
Eli Lilly's experimental drug retatrutide has demonstrated significant weight loss in adults with type 2 diabetes, with participants losing up to 60 pounds. In the TRIUMPH-1 study, patients achieved 28.3% weight loss at 80 weeks. The drug is not yet FDA-approved, but Eli Lilly plans to file for regulatory approval in the first quarter of 2027.
Why it matters
The weight loss results from retatrutide are substantial, especially for patients with type 2 diabetes who often struggle with weight management. The drug's potential approval could provide a new treatment option for obesity and type 2 diabetes. Retatrutide works as a triple agonist, targeting three hormones that regulate appetite and metabolism.
What is confirmed
- Participants in the TRIUMPH-1 study achieved 28.3% weight loss at 80 weeks.
- Patients on the highest dose of retatrutide lost an average of 18.8% of their body weight, compared to 5.1% for those receiving a placebo.
- Eli Lilly intends to file for regulatory approval of retatrutide in the first quarter of 2027.
- In TRIUMPH-2, adults with obesity or overweight and type 2 diabetes lost up to an average of 49.6 lbs (20.8%).
Still unconfirmed
- Some doctors are comparing retatrutide's results to those of surgical interventions.
What to watch next
- FDA approval decision
- Regulatory filing in Q1 2027
- Additional phase 3 trial results
confidence 85%Sources used for this update (8)
- thepeptideinstitute.org — Retatrutide phase 3 results are in. Here is what the TRIUMPH ...
- www.cnbc.com — Novo's next-generation obesity drug shows 25% weight loss in women in late-stage analysis
- www.nytimes.com — Latest Polls
- kures.co — Retatrutide Results: What Trial Participants Experienced
- nowpatient.com — Retatrutide: The most powerful weight-loss drug yet? New ...
- welltica.com — Eli Lilly’s next shot after Ozempic hit about 60 pounds in ...
- topics.consensus.app — Randomized trial shows significant weight loss in adults with ...
- www.finanznachrichten.de — Eli Lilly and Company: Lilly's triple agonist, retatrutide ...
-
Eli Lilly Retatrutide Phase III Trials Show Significant Weight Loss in Diabetes Patients
Eli Lilly's experimental once-weekly injection retatrutide helped adults with obesity and type 2 diabetes lose substantial weight in Phase III clinical trials. In the TRIUMPH-1 study, participants achieved 28.3% weight loss at 80 weeks. Other data indicates patients on the highest dose lost an average of 18.8% of their body weight, compared to 5.1% for those receiving a placebo. While the drug improves blood sugar levels, it is not FDA-approved. Eli Lilly intends to file for regulatory approval in the first quarter of 2027.
Why it matters
Retatrutide is a triple-hormone receptor agonist designed for metabolic management. The TRIUMPH-2 study involved 1,152 patients with type 2 diabetes. These results challenge existing assumptions regarding the design of diabetes weight-loss trials.
What is confirmed
- Retatrutide is a once-weekly injected drug developed by Eli Lilly.
- The drug is not currently FDA-approved.
- TRIUMPH-1 trial participants showed 28.3% weight loss at 80 weeks.
- Adults with obesity and type 2 diabetes on the highest dose lost an average of 18.8% of their body weight.
- Placebo participants lost an average of 5.1% of their body weight over 80 weeks.
- The TRIUMPH-2 study included 1,152 patients with type 2 diabetes.
Still unconfirmed
- Eli Lilly plans to file for approval in Q1 2027.
- The drug is considered a risky research peptide.
What to watch next
- FDA approval filing in Q1 2027
- Publication of full TRIUMPH-2 data in The Lancet
confidence 90%Sources used for this update (5)
- www.newsweek.com — When Could Reta Be Available? Weight-Loss Drug Retatrutide ...
- tirzepatidereview.com — Retatrutide in 2026: TRIUMPH Results & Approval Status
- knowridge.com — New Drug Leads to Strong Weight Loss in Diabetes
- www.geo.tv — What is Retratrutide? New drug helps diabetes patients lose ...
- www.clinicaltrialvanguard.com — Retatrutide’s TRIUMPH-2 Data Forces a Reckoning With How We ...
-
Eli Lilly Triple-Action Weight Loss Drug Retatrutide Yields Major Results
Participants with Type 2 diabetes achieved substantial weight reductions in a Phase III clinical trial evaluating Eli Lilly's experimental once-weekly injection, retatrutide. The triple-hormone receptor agonist delivered major weight loss and improved blood sugar control over an 80-week period. While patients lost up to 60 pounds or nearly 50 pounds on average at the highest tested dose, the trial also recorded side effects including nausea and diarrhea, alongside higher discontinuation rates compared to older medications. The therapy remains unapproved as the company prepares further regulatory submissions.
Why it matters
Eli Lilly continues to expand its portfolio beyond existing treatments like semaglutide and tirzepatide by targeting three hormone receptors simultaneously. The experimental drug aims to tackle obesity and Type 2 diabetes concurrently in patients who often struggle to drop weight using standard obesity medications. Phase III clinical data provides strong efficacy results, though safety profiles and discontinuation rates remain a core focus for the company and regulators.
What is confirmed
- Retatrutide is an experimental once-weekly injection developed by Eli Lilly to treat obesity and Type 2 diabetes.
- The Phase III clinical trial TRIUMPH-2 evaluated the efficacy and safety of retatrutide.
- Retatrutide activates three hormone receptors at once.
- The 80-week trial showed substantial weight loss and better blood sugar control alongside more nausea and diarrhea.
Still unconfirmed
- Patients on the drug combination for Eli Lilly experienced discontinuation rates that were far higher than those seen with Zepbound.
What to watch next
- Further regulatory submissions by Eli Lilly to the FDA
- Additional data releases from Phase III clinical trials
confidence 100%Sources used for this update (5)
- www.marketbeat.com — Eli Lilly and Company (LLY) FDA Approvals, PDUFA Dates & Drug ...
- scitechdaily.com — Beyond Ozempic? New Weight Loss Drug Shows Stunning Results ...
- www.fool.com — This Drug Combination for Eli Lilly Generated Significantly ...
- medicalxpress.com — Triple-action drug retatrutide delivers major weight loss for ...
- theindianpractitioner.com — Retatrutide Shows Significant Weight Loss in People with ...
-
Eli Lilly Diabetes Drug Retatrutide Yields Major Weight Loss
Adults with Type 2 diabetes achieved significant weight reductions using Eli Lilly's experimental triple-hormone receptor agonist retatrutide in phase III clinical trials. Participants receiving the highest tested dose lost an average of nearly 50 pounds, or up to 23% of their body weight, at week 80. The therapy simultaneously improved blood sugar control for patients who typically face challenges losing substantial weight on standard obesity medications. While clinical trial data shows strong efficacy, the treatment remains unapproved as the company prepares further regulatory submissions.
Why it matters
Retatrutide targets three distinct hormone receptors to address both obesity and metabolic function in diabetes patients. This mechanism represents an advance over older single- or dual-target therapies that historically produced more modest weight loss results for individuals with Type 2 diabetes.
What is confirmed
- Retatrutide cut body weight by 20.8% in a Phase 3 Type 2 diabetes trial.
- People with Type 2 diabetes lost an average of nearly 50 pounds on the highest dose of Eli Lilly's experimental medication retatrutide.
Still unconfirmed
- People receiving the highest tested dose of EloraTZP lost an average of 23% weight loss.
What to watch next
- Official regulatory submission filings by Eli Lilly
- Additional phase III safety and efficacy data releases
confidence 100%Sources used for this update (4)
- vegnews.com — Have Type 2 Diabetes? You Can Still Eat Carbs on a Vegan Diet | VegNews
- www.diabetes.co.uk — New triple-action treatment produces 23% weight loss in ...
- theprimary.com — Experimental triple hormone drug reduces body weight in ...
- article.wn.com — Lilly's retatrutide GLP-1 delivers average weight loss of 50 ...
-
Retatrutide Trial Shows Significant Weight Loss in Type 2 Diabetes
Adults with obesity and type 2 diabetes achieved substantial weight loss using Eli Lilly's experimental triple hormone receptor agonist retatrutide in phase III clinical trials. Participants receiving a 12 mg dose experienced weight reductions ranging from 18.8% to 20.8% at week 80, significantly outperforming placebo groups. The therapy targets three different hormone receptors, offering a new approach for patients with diabetes who historically struggle to lose as much weight on standard obesity medications. While clinical data highlights strong efficacy and blood sugar improvements, the treatment remains unapproved pending further regulatory submissions.
Why it matters
Traditional metabolic medicines have transformed chronic weight management, but patients dealing with type 2 diabetes typically face greater difficulty shedding pounds than individuals without diabetes. The emergence of second-wave therapies aims to overcome these limitations through multi-agonist mechanisms that combine gut hormones like GLP-1 with additional metabolic pathways. Eli Lilly plans to submit retatrutide for FDA approval in the first quarter of 2027.
What is confirmed
- Adults with obesity and type 2 diabetes lost an average 18.8% of body weight at week 80 with retatrutide 12 mg, versus 5.1% with placebo.
- Participants who received 12 mg of retatrutide for 80 weeks lost 20.8 percent of their body weight in the TRIUMPH-2 study data.
- Retatrutide is an experimental weekly injection designed to copy multiple hormone effects.
Still unconfirmed
- Retatrutide's FDA filing is planned for Q1 2027.
- Eli Lilly released its first-ever clinical trial data for a new dual-action treatment combining Mounjaro with an experimental drug named elora in late September 2026.
What to watch next
- Eli Lilly's planned FDA filing for retatrutide in the first quarter of 2027
- Regulatory decisions regarding next-generation obesity and diabetes treatments expected in late 2026 and 2027
confidence 95%Sources used for this update (11)
- theclinicaltimes.com — Retatrutide led to weight loss in phase III trial of adults ...
- www.onedaymd.com — GLP-1 2.0: The Next Generation of Obesity Drugs - onedaymd.com
- health.yahoo.com — Eli Lilly’s New Drug Combo Just Set A Record For Weight Loss ...
- chicago.suntimes.com — Illinois Gov. JB Pritzker lost 80 pounds with help from GLP-1 ...
- knowridge.com — New Drug Delivers Major Weight Loss in Type 2 Diabetes
- blavity.com — Eli Lilly's New Drug Combo Just Set A Record For Weight Loss ...
- www.technologyreview.com — We’re still figuring out the side effects of GLP-1 weight-loss drugs
- www.zmescience.com — New Weight-Loss Drug Helps People With Type 2 Diabetes Lose 21% of Their Body Weight
- www.healthcount.app — Eloralintide Plus Tirzepatide (EloraTZP), Explained | Healthcount
- vialaudit.com — Retatrutide Phase 3 results: TRIUMPH-2 in The Lancet
- Longevity.Technology — Lilly’s twin bets reshape diabetes weight loss
-
Retatrutide Trial Data Shows 23.4% Weight Loss in Adults with Type 2 Diabetes
Eli Lilly's experimental triple hormone receptor agonist retatrutide produced a 23.4% weight loss in adults with type 2 diabetes and a BMI of 35 or higher, according to results published in The Lancet. The drug also normalized blood sugar in 40% of patients and reduced A1C levels. While trial data shows patients can shed up to 60 pounds, the treatment remains unapproved. Clinical results indicate the drug improves blood sugar control and lowers inflammation with manageable gastrointestinal side effects.
Why it matters
Retatrutide is a triple agonist designed to treat obesity and metabolic conditions. It follows a trend of GLP-1 based therapies aimed at chronic weight management. The TRIUMPH-1 and TRIUMPH-2 trials provide the primary data for these efficacy claims.
What is confirmed
- Retatrutide is a triple hormone receptor agonist developed by Eli Lilly.
- Clinical trial results show participants with type 2 diabetes lost up to 60 pounds.
- The Lancet reported a 23.4% weight loss in adults with type 2 diabetes and a BMI of 35 or higher.
- Retatrutide is currently unapproved.
- The drug produced substantial A1C reductions in adults with obesity and type 2 diabetes.
Still unconfirmed
- Retatrutide normalized blood sugar in 40% of patients.
- The drug lowers inflammation.
What to watch next
- Regulatory approval decisions from health authorities
- Results from further TRIUMPH trial phases
- Comparative efficacy data against existing GLP-1 agonists
confidence 95%Sources used for this update (8)
- jen.jiji.com — Mancini: "Good at getting back into the game, a more than positive balance sheet"
- www.medicaldaily.com — Peer-Reviewed Retatrutide Data Show 23.4% Weight Loss in ...
- pharmaceutical-journal.com — Triple agonist drug retatrutide shows 21% weight loss in ...
- www.pharmacy.biz — Eli Lilly’s retatrutide can help shed up to 60 pounds of body ...
- www.glp3.wiki — Retatrutide Results and Review: The Weight Loss Data by Dose
- www.sciencetimes.com — New Retatrutide Trial Shows Significant Weight Loss and ...
- sleepworldmagazine.com — Retatrutide Delivers Significant Weight Loss and A1C ...
- www.newser.com — Eli Lilly Diabetes Drug Spurs Record Weight Loss in Trials
-
Eli Lilly Weight Loss Drug Trial Shows Substantial Results
Eli Lilly reports that participants with type 2 diabetes lost up to 60 pounds in a trial of its experimental weight-loss drug, retatrutide. The triple agonist compound delivered significant weight reduction and A1C reduction in patients with obesity and type 2 diabetes. Clinical testing recorded weight loss percentages reaching up to 21 percent and 25 percent in trial settings. Observers describe the experimental treatment as a high-water mark and a powerful obesity drug option for addressing metabolic conditions.
Why it matters
Pharmaceutical companies continue to advance next-generation therapeutics targeting obesity and associated metabolic conditions like type 2 diabetes. Eli Lilly's latest trial data positions its triple agonist compound competitively against existing therapies in the metabolic health sector. Full phase 3 trial results establish concrete benchmarks for efficacy in weight reduction and glycemic control.
What is confirmed
- People with Type 2 diabetes lost up to 60 pounds on Lilly's latest weight loss drug.
- Lilly's experimental drug cuts weight by 21% in a diabetes trial.
- Participants in trials lost up to 25% of their weight.
- Retatrutide is a triple agonist that delivered substantial weight loss and A1C reduction.
What to watch next
- Full phase 3 trial data evaluations by regulatory bodies
- Further announcements regarding commercial availability and pricing
confidence 100%Sources used for this update (15)
- Ars Technica — Most powerful obesity drug yet: People lost up to 25% of weight in trial
- The Guardian — ‘Godzilla’ of weight-loss drugs could provide other important health benefits
- Reuters — Lilly's experimental drug cuts weight by 21% in diabetes trial
- Scientific American — Blockbuster retatrutide trial signals a ‘new high-water mark’ for weight-loss drugs
- NBC News — People with Type 2 diabetes lost up to 60 pounds on Lilly’s latest weight loss drug
- Eli Lilly — Lilly's triple agonist, retatrutide, delivered substantial weight loss and A1C reduction, underscoring its potential promise for people with obesity and type 2 diabetes
- Fierce Biotech — Lilly sets up next-gen obesity battle with full phase 3 retatrutide data
- Time Magazine — Eli Lilly’s Experimental Weight-Loss Drug Shows Promising Results
- dictionary.cambridge.org — PEOPLE | English meaning - Cambridge Dictionary
- nypost.com — people magazine | Latest News | New York Post
- pocketmags.com — People Magazine Subscriptions and 05-10-2026 Issue - Pocketmags
- www.dictionary.com — PEOPLE Definition & Meaning | Dictionary.com
Community Sentiment: How do you assess this situation?
Voice your perspective · Real-time aggregated sentiment from the Live Feeds community